Home › Funds › 683 Capital Management, LLC › ALNY

683 Capital Management, LLC position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

683 Capital Management, LLC reported holding 82,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$20.2M, representing 0.90% of its reported portfolio and ranking #25 among its reported holdings. 683 Capital Management, LLC has disclosed ALNY holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)82.00K sh
Reported value held$20.23M
Portfolio Weight0.90%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How 683 Capital Management, LLC's ALNY position evolved

683 Capital Management, LLC first disclosed a stake in ALNY in Q3 2023 at 10,000 shares (US$1.8M). The position peaked in Q3 2025 at 135,700 shares, worth US$61.9M. Across 12 filings, 683 Capital Management, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 82,000 shares valued at US$20.2M — an increase of 47,000 shares quarter over quarter.. Notable position changes include a 243% increase in Q2 2024 (shares rose 13% over the following quarter), a 176% increase in Q2 2025 (shares rose 40% over the following quarter), a 455% increase in Q1 2026 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 10.00K $1.77M New
Q1 2024 35.80K $5.35M New
Q2 2024 122.90K $29.86M Add
Q3 2024 123.30K $33.91M Hold
Q4 2024 58.70K $13.81M Reduce
Q1 2025 51.20K $13.83M Reduce
Q2 2025 141.30K $46.08M Add
Q3 2025 135.70K $61.88M Reduce
Q4 2025 3.78K $1.50M Reduce
Q1 2026 21.00K $6.95M Add
Q2 2026 35.00K $10.54M Add
Q3 2026 82.00K $20.23M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$597.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has 683 Capital Management, LLC held ALNY?

683 Capital Management, LLC has disclosed ALNY holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

What is 683 Capital Management, LLC's current position in ALNY?

As of Q3 2026, 683 Capital Management, LLC holds 82.00K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $20.23M, representing 0.90% of its reported portfolio and ranking #25.

Has 683 Capital Management, LLC been buying or selling ALNY?

In the latest 13F filing (Q3 2026), 683 Capital Management, LLC increased its position in ALNY. The position peaked in Q3 2025 at 135.70K shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.